Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...

Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...

Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. As of March 4, 2025, the average one-year price target for CervoMed ...